Market Overview:
The helicobacter pylori diagnostics market is experiencing rapid growth, driven by rising prevalence, non-invasive test demand, and technological advancements. According to IMARC Group's latest research publication, “Helicobacter Pylori Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033”. The global helicobacter pylori diagnostics market size reached USD 585.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 918.8 Million by 2033, exhibiting a growth rate (CAGR) of 4.72% during 2025-2033.
This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.
Grab a sample PDF of this report: https://www.imarcgroup.com/helicobacter-pylori-diagnostics-market/requestsample
Our report includes:
- Market Dynamics
- Market Trends And Market Outlook
- Competitive Analysis
- Industry Segmentation
- Strategic Recommendations
Factors Affecting the Growth of the Helicobacter Pylori Diagnostics Industry:
- Rising Prevalence:
The worldwide incidence of Helicobacter pylori (H. pylori) infections is a key factor for growth in the diagnostics market. An estimated half of the global population is infected with H. pylori and given this high incidence, there is a continuous, significant demand for reliable diagnostics. Given the high prevalence of H. pylori, particularly in developing areas due to poor sanitation and hygiene, there is even greater need for accurate, efficient testing. Furthermore, there's a growing realization among both healthcare professionals and the public that H. pylori is responsible for serious gastrointestinal conditions (eg, gastritis, peptic ulcer disease, gastric cancer), which may lead to greater consumer awareness of testing options and hold more value in early detection and timely treatment, both of which foster growth in the market.
- Non-Invasive Test Demand:
Patients and physicians are beginning to prefer non-invasive diagnostic methods for H. pylori. As a result, non-invasive testing will generate a different market structure. Non-invasive tests like urea breath tests (UBT) and stool antigen tests (SAT) are materials patients and physicians are choosing over traditional invasive urea breath tests (UBT) and stool antigen tests (SAT). Patient preference for non-invasive tests is built upon patient comfort, ease, reduced risk of adverse events, and often a lower cost. The continual improvements in non-invasive test technologies with respects to accuracy, sensitivity, and quicker turn-around-times, also helps market acceptability and market growth. This is bringing in a wave of innovation to make useable and easy means of non-invasive tests for patients.
- Technological Advancements:
H. pylori diagnostics is undergoing rapid technological change, enhancing both accuracy and accessibility. New molecular diagnostics, including molecular breath tests and PCR (polymerase chain reaction), represent a leap over antiquated tests based on culture and serology, with higher sensitivity and specificity to allow more definitive detection of the genetic material of the bacterium. Some of the most recent developments in the field utilize AI (artificial intelligence) and digital health to streamline workflow for diagnostics, provide better analyses of data, and allow diagnostics and telehealth to occur remotely. These advancements are improving the way professionals can diagnose H. pylori and improve processes for H. pylori management across the world in the future.
Leading Companies Operating in the Global Helicobacter Pylori Diagnostics Industry:
- Abbott Laboratories
- Avanos Medical, Inc.
- Biohit Oyj
- Bio-Rad Laboratories, Inc.
- Cardinal Health Inc.
- CerTest Biotec S.L.
- Coris BioConcept (Avacta Group)
- CTK Biotech Inc. (SSI Diagnostica A/S Group)
- Epitope Diagnostics, Inc.
- Gulf Coast Scientific Inc.
- Meridian Bioscience, Inc. (SD Biosensor Inc.)
- Quest Diagnostics Incorporated
- Quidel Corporation
- Thermo Fisher Scientific Inc.
Helicobacter Pylori Diagnostics Market Report Segmentation:
By Test Type:
- Non-Invasive Test
- Invasive Test
Non-invasive test represents the largest segment as they do not require specialized equipment or skilled personnel to administer, making them more accessible in various healthcare settings.
By Method:
- Laboratory Based Test
- Point of Care Test
Laboratory based test accounts for the majority of the market share due to its reliability, accuracy, and ability to detect the bacterium efficiently.
By End User:
- Diagnostics Laboratories
- Hospitals
- Others
Diagnostics laboratories hold the biggest market share owing to the growing prevalence of H. pylori infection across the globe.
Regional Insights:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position in the helicobacter pylori diagnostics market on account of advanced healthcare infrastructure coupled with a high prevalence of gastrointestinal disorders.
Research Methodology:
The report employs a comprehensive research methodology, combining primary and secondary data sources to validate findings. It includes market assessments, surveys, expert opinions, and data triangulation techniques to ensure accuracy and reliability.
Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Comments
0 comment